Pathogenesis and toxins

Immune discrepancies during *in vitro* granuloma formation in response to *Cutibacterium* (formerly *Propionibacterium*) *acnes* infection

Guillaume Ghislain Aubin [a, b], Grâce Ada Da Silva [c], Yoshinobu Eishi [d], Cédric Jacqueline [a], Frédéric Altare [c], Stéphane Corvec [b, c, 1], Karim Asehnoune [a, *, 1]

[a] EA3826, Laboratory of Clinical and Experimental Therapeutics of Infections, IRS 2, Nantes University, Nantes, France
[b] Bacteriology and Hygiene Unit, CHU Nantes, France
[c] CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
[d] Department of Human Pathology, Tokyo Medical and Dental University, Tokyo, Japan

ARTICLE INFO

ABSTRACT

Cutibacterium (formerly *Propionibacterium*) *acnes* is involved in chronic/low-grade pathologies such as sarcoidosis or prosthetic joint infection (PJI). In these diseases, granulomatous structures are frequently observed. In this study, we induced a physiological granulomatous reaction in response to different well-characterized clinical *C. acnes* isolates in order to investigate the cellular process during granuloma formation. Three *C. acnes* isolates selected according to their origin (PJI, sarcoidosis and acne) were typed by MLST. All *C. acnes* isolates generated granulomatous structures in our experimental conditions. The bacterial burden was better controlled by granulomas induced by the sarcoidosis *C. acnes* isolate. The PJI *C. acnes* isolate, belonging to CC36, promoted the recruitment of CD8$^+$ lymphocytes inside the granuloma. In contrast, the acne and sarcoidosis *C. acnes* isolates, belonging to phylotypes IA$_1$/CC18 and IA$_2$/CC28, respectively, generated a higher number of granulomas and promoted the recruitment of CD4$^+$ lymphocytes inside the granuloma. Our results provide new evidence supporting the role of *C. acnes* in the development of sarcoidosis and new explanations concerning the mechanisms underlying PJI due to *C. acnes*.

© 2017 Elsevier Ltd. All rights reserved.

1. Introduction

Cutibacterium acnes is an important part of the normal flora of human skin, living in and around sweat glands and sebaceous follicles. The pathogenicity of *C. acnes* has long been restricted to skin conditions [1]. Although described as a commensal bacterium with a low pathogenicity, its involvement has been reported in many clinical entities [2]. In the context of chronic/low-grade pathologies, the two main features of *C. acnes* infection are sarcoidosis and prosthetic joint infection (PJI). The link between these two pathologies is the presence of granulomatous structures in response to the infection.

Sarcoidosis is a systemic disease with an unknown etiology, which is characterized by non-caseating granulomas found primarily in the lung [3]. While the accurate cause of sarcoidosis remains unknown, it seems that the pathogenesis results from the combination of genetic susceptibility and exposure to specific antigens, either environmental or infectious [3]. Nevertheless, *C. acnes* has been suspected of being involved in the development of sarcoidosis and has frequently been cultured out of lymph nodes from sarcoidosis patients [4,5] and localized within sarcoidosis granulomas [6]. Additionally, *C. acnes* has been shown to drive differential cytokine responses in the peripheral blood mononuclear cells of sarcoidosis patients [7]. In 2—14% of cases, *C. acnes* has also been identified as the cause of various implant-associated infections, including PJI, particularly in shoulder prostheses, spine implant surgery, and hip and knee prostheses [8,9]. We previously reported that *C. acnes* isolates belonging to clonal complex (CC) 36 were more frequently observed in PJI [10]. These PJI are also characterized by granulomatous structures in the tissues next to the material [11—13].

Some granuloma-producing animal models of sarcoidosis have been proposed using different bacteria and bacterial products

[14–16]. On the other hand, host-bacterial interaction in PJI is usually assessed using a foreign-body infection model with guinea pigs or rabbits [17,18]. To date, no study has focused on the granuloma formation next to the material implanted. Moreover, animal models remain technically and ethically unsuitable to evaluate a large collection of isolates.

Thus, the cellular organization and host-bacteria interactions within complex granulomas have not been well-described to date. To our knowledge, there is no relevant model that illustrates *in vitro* granulomas leading to clinical extrapolation. To develop such a model, we used freshly collected human peripheral blood mononuclear cells (PBMCs) from healthy individuals. This enabled us to evaluate the relevance of an *in vitro* persistence model of *C. acnes* in human blood cell phagocytes in a cellular and physiological environment that mimics the *in vivo* situation. In this study, we induced a physiological granulomatous reaction in response to different *C. acnes* isolates in order to investigate the cellular process during granuloma formation.

2. Material and methods

2.1. Bacterial strains

The *C. acnes* ATCC6919 isolate (CC18, phylotype IA1) came from the American Type Culture Collection (ATCC). Its clinical origin is acne lesion and its genome has been sequenced (Genebank accession number 1174878). The *C. acnes* BL clinical isolate (CC36, phylotype IB) was isolated at Nantes University Hospital from a PJI. Its genome was recently sequenced [19]. Lastly, the *C. acnes* S8 strain (CC28, phylotype IA$_2$) was kindly provided by Professor Y. Eishi of the Department of Human Pathology, Tokyo Medical and Dental University, Tokyo, Japan. This strain was isolated from the lymph node of a sarcoidosis patient [20]. These isolates have previously been typed by MLST [20,21].

2.2. Human peripheral blood mononuclear cells and Cutibacterium acnes co-culture

Peripheral blood samples were obtained from healthy volunteers at the *Etablissement Français du Sang*, Pays de la Loire (Nantes, France). PBMCs were isolated by gradient density sedimentation as previously described [22]. All the analyses presented were performed according to the principles expressed in the Helsinki Declaration. Co-culture protocols were based on previously described *Mycobacterium tuberculosis* granuloma experiments by Altare et al. [23]. In brief, PBMCs were adjusted to a final concentration of 10^6 cells/mL per well. Then, *C. acnes* cells were added to the blood cells and incubated at 37 °C, 5% CO_2. Cellular aggregation was followed daily using light microscopy. Uninfected PBMCs were used as the negative control. At various time points of incubation (day 3 and day 7), granuloma structures were processed for microscopic observation, as well as for flow cytometric analysis.

2.3. Colony-forming unit assay

C. acnes growth was measured using a colony-counting technique (colony-forming unit, CFU). After co-culture at different time points, the cells were washed three times with phosphate-buffered saline. Cells in the wells were lysed with Triton ×100 to release the internalized bacteria. Serial dilutions were determined according to the original bacterial number in the culture. Suspensions were spread on Schaedler plates and *C. acnes* colonies were counted after 5 days of incubation at 37 °C under an anaerobic atmosphere. The CFU/mL data obtained corresponded to the bacterial load within the granulomas.

2.4. Flow cytometry

The granuloma structures from co-culture plates were washed twice in phosphate-buffered saline containing 2% FBS and collected at different time points under light microscopy. The cells were suspended in the same buffer to a final volume of 200 μL and stained with a combined fluorescent-conjugated antibodies mix. The antibodies were specific to CD3-BV421 (clone UCHT1, BD Biosciences), CD4-FITC (clone RPA-T4, BD Biosciences), CD8-APC (clone RPA-T8, BD Biosciences), and NKp46-Pecy7 (clone 9E2/NKp46, BD Biosciences). The cells were incubated for 30 min at 4 °C in the dark, washed twice with 2% FBS in phosphate-buffered saline and analyzed by flow cytometry. After gating on CD3 lymphocytes, the CD3$^+$ population was separated into CD4$^+$ and CD8$^+$ T cells. Natural killer cells were gated out from the CD3$^-$ population. All data were acquired using an LSR II instrument (BD Biosciences) and analyzed with FlowJo software version 9.4.10 (Tree Star Inc.) and DIVA software version 6.2 (BD).

3. Results

3.1. PBMCs infected by the sarcoidosis C. acnes isolate generated a higher number of granulomatous structures

The first step in the development of an *in vitro* human model of *C. acnes* granulomas was to induce recruitment of PBMCs around live *C. acnes*. We first determined the optimal multiplicity of infection (MOI) of *C. acnes* for use in subsequent experiments. The monocyte:bacteria MOI ratios studied were 10,000:1, 1000:1, 100:1 and 10:1. The MOIs 100:1 and 10:1 caused premature destruction of granulomatous structures due to an uncontrolled increase in the bacterial load. By contrast, at an MOI of 10,000:1, no cellular aggregation resembling granulomatous structures was observed under light microscopy. The MOI of 1000:1 was chosen for use in subsequent experiments.

PBMCs from five healthy immunocompetent subjects were challenged with the three *C. acnes* isolates. Cell cultures were maintained for up to 14 days post-infection and the occurrence of immune infiltrates was quantified on day 7 and day 14 by light microscopy observation. Cellular aggregation was visible three days after challenge. Between days 4 and 14, distinguishable multicellular and multilayered structures similar to granuloma-like structures were identified under infection conditions. At that time, all the *C. acnes* isolates tested were able to induce dense aggregates. Fig. 1A shows the representative compact immune infiltrates observed with each of the three clinical isolates of *C. acnes* seven days after challenge. On day 7 post-infection, the average number of these structures was between 50 (*C. acnes* BL) and 74 (*C. acnes* S8) per well (Fig. 1B). On day 14, the size of the structures increased for all isolates with no significant difference compared to day 7. The formation of these structures against *C. acnes* also varied depending on the phylogenetic characteristic of each isolate. Fig. 1B shows that *C. acnes* S8 (CC28) developed significantly more granuloma-like structures than *C. acnes* BL (CC36) on day 7 after infection (p < 0.05). *C. acnes* BL developed significantly fewer granuloma-like structures than *C. acnes* ATCC6919 (CC18) and *C. acnes* S8 on day 14 after infection (p < 0.05).

3.2. Granulomas induced by the PJI C. acnes isolate exerted a greater infection control

After infection of human immune cells, the *C. acnes* burden was assessed by a colony-counting method at day 7 and day 14. The results of the *C. acnes* burden were expressed by the mean of CFU/mL for five subjects. They showed no significant difference in

Fig. 1. Granuloma-response to *Cutibacterium acnes*.
The granuloma-response to *C. acnes* was analyzed by infecting the PBMCs from 5 donors (MOI of 1000:1).
A. Light-microscopic observation of representative granulomas from donors after seven days of infection with *C. acnes*.
B. Number of specific granulomas per culture-well at different times of infection with *C. acnes*. *p < 0.05.
C. The granuloma-response was followed by counting the colony-forming units (CFU/mL) at different time points. *p < 0.05.

C. acnes growth between day 7 and day 14 for all *C. acnes* isolates (Fig. 1C). Interestingly, a strong variability in the *C. acnes* burden was identified on day 7 and day 14 post-infection between ATCC6919/S8 and BL *C. acnes* isolates. The *C. acnes* burden discrepancy was significant between S8 (CC28) and BL (CC36) *C. acnes* isolates (p < 0.05).

The sarcoidosis *C. acnes* isolate led to a CD4$^+$ T lymphocyte response whereas the PJI *C. acnes* isolate led to a CD8$^+$ T lymphocyte response within granulomatous structures.

We then used flow cytometry to analyze the lymphocyte subsets in the granulomatous structures. The granulomatous structures from 9 healthy donors were isolated from co-culture plates 14 days after infection with the three *C. acnes* isolates (ATCC6919, S8 and BL). The total numbers of lymphocytes, T cells (CD3$^+$), helper T cells (CD3$^+$CD4$^+$), cytotoxic T cells (CD3$^+$CD8$^+$) and NK cells (Nkp46 + CD3$^-$) were analyzed. The means and standard deviations of each lymphocyte subset on day 14 post-infection are presented in Fig. 2. Interestingly, we observed a significantly lower percentage of the granuloma-infiltrated CD4$^+$ T lymphocytes in response to the *C. acnes* BL isolate (CC36) compared to the other *C. acnes* isolates on day 14 (p < 0.05). Consequently, there was a significantly higher percentage of infiltrated CD8$^+$ T lymphocytes in response to *C. acnes* BL isolate compared to the other *C. acnes* isolates on day 14 (p < 0.05). These differences were also significant compared to non-infected cells. The percentage of the NK cell subset within the granulomatous structures did not show significant results. We observed a higher variability between donors in this cell population.

Fig. 3 shows an analysis of the lymphocyte subsets in the granulomatous structures from 5 healthy donors isolated from co-culture plates on day 7 and day 14 post-infection with *C. acnes* (ATCC6919, S8 and BL). We observed a significant decrease in CD8$^+$ T lymphocytes in response to *C. acnes* ATCC6919 and *C. acnes* S8 between day 7 and day 14 (p < 0.05).

4. Discussion

To the best of our knowledge, we have developed for the first time an *in vitro* model of granuloma formation in response to *C. acnes* infection. In our experimental conditions, we were able to generate granulomatous structures easily with all the clinical strains tested. Granulomatous structures are immune responses to control intracellular bacterial development [24], even though *C. acnes* is not strictly considered an intracellular pathogen compared to *Mycobacterium tuberculosis* or *Listeria monocytogenes*. However, we recently showed that *C. acnes* can be internalized by osteoblasts and osteoclasts [25]. Other researchers have also demonstrated this internalization with other cell lines: HaCaT and HEKa [26], THP-1 [27], and HEK293T [28]. We observed some discrepancies between the granuloma numbers generated in response to the *C. acnes* strains tested. Interestingly, strain S8 recovered from the lymph node of a sarcoidosis patient generated the highest number of granulomas. Moreover, the bacterial burden inside the granulomas was significantly higher with this strain. Based on its clinical origin, we suggest that strain S8 harbored several antigens leading to the formation of granulomatous structures. From a phylogenetic point of view, we have previously demonstrated that *C. acnes* belonging to CC18/28 are more internalized by bone cells than CC36 strains [25]. We also observed this behavior with CD14$^+$ monocytes (personal data). Herein, the granulomatous reaction was stronger against the CC18/28 strains. On the other hand, the low internalization level of the CC36 strain could explain the poor

Fig. 2. Recruitment of cell subsets in *Cutibacterium acnes* granuloma.
The granuloma structures were collected at day 14 from co-culture plates, and stained with a cocktail of fluorescent-conjugated antibodies specific to CD3, CD4, CD8, and NKp46. The cells were analyzed by flow cytometry after gating on CD3 lymphocytes: the CD3$^+$ population was separated into conventional CD4$^+$ and CD8$^+$ T cells. Natural killer cells were gated from the CD3$^-$ population. CD4$^+$, CD8$^+$ and NK lymphocytecells into granulomas (n = 9 donors). All data were acquired using a LSR II flow cytometer instrument (BD Biosciences) and analyzed with FlowJo software version 10 (Tree Star Inc) and DIVA software version 6.2 (BD). *P < 0.05.


Fig. 3. Recruitment of cell subsets in *Cutibacterium acnes* granuloma.
The granuloma structures were collected at different times points from co-culture plates, and stained with a cocktail of fluorescent-conjugated antibodies specific to CD3, CD4, CD8, and NKp46. CD4$^+$, CD8$^+$ and NK lymphocyte cells into granulomas on day 7 (d7) and day 14 (d14) (n = 5 donors). All data were acquired using a LSR II flow cytometer instrument (BD Biosciences) and analyzed with FlowJo software version 10 (Tree Star Inc) and DIVA software version 6.2 (BD). *p < 0.05.

infection control observed (*i.e.* fewer granulomas and a low bacterial burden) in response to the infection. However, 35 *C. acnes* isolated from the lymph nodes of sarcoidosis patients exhibited different internalization levels with HEK293T cells [28] and recently Minegishi *et al.* reported the same conclusion [20]. Unfortunately, the discrepancies between the molecular typing methods used in our studies prevent us from discussing our results from the CC perspective [29]. Nevertheless, according to their phylotype, the different *C. acnes* abilities leading to their interaction with immune cells has been previously described with a model of skin explants [30]. In this study, Jasson *et al.* proposed different proinflammatory profiles for the five *C. acnes* types from the strongest to the lowest: *C. acnes* type III, II, IC, IA1, IB.

As previously described, our model can reproduce the immune reaction against a microorganism *in vitro* [23,31,32]. The *C. acnes* strain isolated from PJI induced a higher recruitment of CD8$^+$ lymphocytes inside the granuloma. In patients suffering from *C. acnes* PJI, these lymphocytes, through their cytotoxic activity, may cause tissue damage leading to osteoclast activation and thereafter aseptic loosening of the prosthesis [33], frequently observed during chronic and low-grade infections due to *C. acnes*

[34]. In contrast, the high recruitment of CD4$^+$ lymphocytes in response to sarcoidosis and acne isolates is in accordance with previous studies [35,36].

This study presents several limitations: first, we studied a small number of bacterial strains and secondly, we observed some variations between blood donors. However, this *in vitro* human granuloma model can be used to analyze the human granulomatous response to viable bacteria. By taking into account the representative immune cells, cell maturation studies can be suitably adapted and cell trafficking can be followed. These studies may be carried out to determine whether particular cells can migrate to the granulomas and subsequently leave these structures. Further work is needed to define the balance between pro- and anti-inflammatory cytokines, which provide efficient protection against *C. acnes* infection.

To conclude, the pathogenesis of sarcoidosis or PJI due to *C. acnes* remains poorly understood in humans. This model appears to be a possible alternative assay to animal models for studying the immune response to *C. acnes* infection. Our results provide new evidence supporting the role of *C. acnes* in the development of sarcoidosis and new explanations concerning the mechanisms

underlying PJI due to *C. acnes*.

Reference

[1] C. Beylot, N. Auffret, F. Poli, J.-P. Claudel, M.-T. Leccia, P. Del Giudice, B. Dreno, *Propionibacterium acnes*: an update on its role in the pathogenesis of acne, J. Eur. Acad. Dermatol Venereol. 28 (2014) 271—278, http://dx.doi.org/10.1111/jdv.12224.

[2] G.G. Aubin, M.E. Portillo, A. Trampuz, S. Corvec, *Propionibacterium acnes*, an emerging pathogen: from acne to implant-infections, from phylotype to resistance, Med. Mal. Infect. (2014), http://dx.doi.org/10.1016/j.medmal.2014.02.004.

[3] D. Valeyre, A. Prasse, H. Nunes, Y. Uzunhan, P.-Y. Brillet, J. Müller-Quernheim, Sarcoidosis, Lancet 383 (2014) 1155—1167, http://dx.doi.org/10.1016/S0140-6736(13)60680-7.

[4] C. Abe, K. Iwai, R. Mikami, Y. Hosoda, Frequent isolation of *Propionibacterium acnes* from sarcoidosis lymph nodes, Zentralbl Bakteriol. Mikrobiol. Hyg. A 256 (1984) 541—547.

[5] M.-M. Zhao, S.-S. Du, Q.-H. Li, T. Chen, H. Qiu, Q. Wu, S.-S. Chen, Y. Zhou, Y. Zhang, Y. Hu, Y.-L. Su, L. Shen, F. Zhang, D. Weng, H.-P. Li, High throughput 16SrRNA gene sequencing reveals the correlation between *Propionibacterium acnes* and sarcoidosis, Respir. Res. 18 (2017) 28, http://dx.doi.org/10.1186/s12931-017-0515-z.

[6] M. Negi, T. Takemura, J. Guzman, K. Uchida, A. Furukawa, Y. Suzuki, T. Iida, I. Ishige, J. Minami, T. Yamada, H. Kawachi, U. Costabel, Y. Eishi, Localization of *Propionibacterium acnes* in granulomas supports a possible etiologic link between sarcoidosis and the bacterium, Mod. Pathol. 25 (2012) 1284—1297, http://dx.doi.org/10.1038/modpathol.2012.80.

[7] H. Furusawa, Y. Suzuki, Y. Miyazaki, N. Inase, Y. Eishi, Th1 and Th17 immune responses to viable *Propionibacterium acnes* in patients with sarcoidosis, Respir. Investig. 50 (2012) 104—109, http://dx.doi.org/10.1016/j.resinv.2012.07.001.

[8] S. Corvec, M.E. Portillo, B.M. Pasticci, O. Borens, A. Trampuz, Epidemiology and new developments in the diagnosis of prosthetic joint infection, Int. J. Artif. Organs 35 (2012) 923—934, http://dx.doi.org/10.5301/ijao.5000168.

[9] U. Furustrand Tafin, S. Corvec, B. Betrisey, W. Zimmerli, A. Trampuz, Role of rifampin against *Propionibacterium acnes* biofilm in vitro and in an experimental foreign-body infection model, Antimicrob. Agents Chemother. 56 (2012) 1885—1891, http://dx.doi.org/10.1128/AAC.05552-11.

[10] G.G. Aubin, J.-P. Lavigne, Y. Foucher, S. Dellière, D. Lepelletier, F. Gouin, S. Corvec, Tropism and virulence of *Cutibacterium* (formerly *Propionibacterium*) acnes involved in implant-associated infection, Anaerobe 47 (2017 Apr 25) 73—78, http://dx.doi.org/10.1016/j.anaerobe.2017.04.009.

[11] W. Zimmerli, P.D. Lew, F.A. Waldvogel, Pathogenesis of foreign body infection. Evidence for a local granulocyte defect, J. Clin. Invest. 73 (1984) 1191—1200, http://dx.doi.org/10.1172/JCI111305.

[12] G. Grammatopoulos, H. Pandit, A. Kamali, F. Maggiani, S. Glyn-Jones, H.S. Gill, D.W. Murray, N. Athanasou, The correlation of wear with histological features after failed hip resurfacing arthroplasty, J. Bone Jt. Surg. Am. 95 (2013) e81, http://dx.doi.org/10.2106/JBJS.L.00775.

[13] R.H. Lusk, E.C. Wienke, T.W. Milligan, T.E. Albus, Tuberculous and foreign-body granulomatous reactions involving a total knee prosthesis, Arthritis Rheum. 38 (1995) 1325—1327.

[14] J. Kishi, Y. Nishioka, T. Kuwahara, S. Kakiuchi, M. Azuma, Y. Aono, H. Makino, K. Kinoshita, M. Kishi, R. Batmunkh, H. Uehara, K. Izumi, S. Sone, Blockade of Th1 chemokine receptors ameliorates pulmonary granulomatosis in mice, Eur. Respir. J. 38 (2011) 415—424, http://dx.doi.org/10.1183/09031936.00070610.

[15] T. Nishiwaki, H. Yoneyama, Y. Eishi, N. Matsuo, K. Tatsumi, H. Kimura, T. Kuriyama, K. Matsushima, Indigenous pulmonary *Propionibacterium acnes* primes the host in the development of sarcoid-like pulmonary granulomatosis in mice, Am. J. Pathol. 165 (2004) 631—639, http://dx.doi.org/10.1016/S0002-9440(10)63327-5.

[16] C.M. Swaisgood, K. Oswald-Richter, S.D. Moeller, J.M. Klemenc, L.M. Ruple, C.F. Farver, J.M. Drake, D.A. Culver, W.P. Drake, Development of a sarcoidosis murine lung granuloma model using Mycobacterium superoxide dismutase A peptide, Am. J. Respir. Cell Mol. Biol. 44 (2011) 166—174, http://dx.doi.org/10.1165/rcmb.2009-0350OC.

[17] Y. Achermann, B. Tran, M. Kang, J.M. Harro, M.E. Shirtliff, Immunoproteomic identification of in vivo-produced *Propionibacterium acnes* proteins in a rabbit biofilm infection model, Clin. Vaccine Immunol. 22 (2015) 467—476, http://dx.doi.org/10.1128/CVI.00760-14.

[18] A.B. Lovati, M. Bottagisio, E. de Vecchi, E. Gallazzi, L. Drago, Animal models of implant-related low-grade infections, A Twenty-Year Rev. Adv. Exp. Med. Biol. (2016), http://dx.doi.org/10.1007/5584_2016_157.

[19] G.G. Aubin, S. Kambarev, A. Guillouzouic, D. Lepelletier, P. Bémer, S. Corvec, Draft genome sequences of four *Propionibacterium acnes* strains isolated from implant-related infections, Genome Announc. 4 (2016), http://dx.doi.org/10.1128/genomeA.01395-16.

[20] K. Minegishi, T. Watanabe, A. Furukawa, K. Uchida, Y. Suzuki, T. Akashi, F. Maruyama, I. Nakagawa, Y. Eishi, Genetic profiles of *Propionibacterium acnes* and identification of a unique transposon with novel insertion sequences in sarcoid and non-sarcoid isolates, Sci. Rep. 5 (2015) 9832, http://dx.doi.org/10.1038/srep09832.

[21] M. Kilian, C.F.P. Scholz, H.B. Lomholt, Multilocus sequence typing and phylogenetic analysis of *Propionibacterium acnes*, J. Clin. Microbiol. 50 (2012) 1158—1165, http://dx.doi.org/10.1128/JCM.r06129-11.

[22] F. Altare, A. Durandy, D. Lammas, J.F. Emile, S. Lamhamedi, F. Le Deist, P. Drysdale, E. Jouanguy, R. Döffinger, F. Bernaudin, O. Jeppsson, J.A. Gollob, E. Meinl, A.W. Segal, A. Fischer, D. Kumararatne, J.L. Casanova, Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency, Science 280 (1998) 1432—1435.

[23] M.-P. Puissegur, C. Botanch, J.-L. Duteyrat, G. Delsol, C. Caratero, F. Altare, An in vitro dual model of mycobacterial granulomas to investigate the molecular interactions between mycobacteria and human host cells, Cell. Microbiol. 6 (2004) 423—433, http://dx.doi.org/10.1111/j.1462-5822.2004.00371.x.

[24] C.J. Martin, A.F. Carey, S.M. Fortune, A bug's life in the granuloma, Semin. Immunopathol. 38 (2016) 213—220, http://dx.doi.org/10.1007/s00281-015-0533-1.

[25] G.G. Aubin, M. Baud'huin, J.-P. Lavigne, R. Brion, F. Gouin, D. Lepelletier, C. Jacqueline, D. Heymann, K. Asehnoune, S. Corvec, Interaction of *Cutibacterium* (formerly *Propionibacterium*) acnes with bone cells: a step toward understanding bone and joint infection development, Sci. Rep. 7 (2017) 42918, http://dx.doi.org/10.1038/srep42918.

[26] T.N. Mak, N. Fischer, B. Laube, V. Brinkmann, M.M.E. Metruccio, K.S. Sfanos, H.-J. Mollenkopf, T.F. Meyer, H. Brüggemann, *Propionibacterium acnes* host cell tropism contributes to vimentin-mediated invasion and induction of inflammation, Cell. Microbiol. 14 (2012) 1720—1733, http://dx.doi.org/10.1111/j.1462-5822.2012.01833.x.

[27] N. Fischer, T.N. Mak, D.B. Shinohara, K.S. Sfanos, T.F. Meyer, H. Brüggemann, Deciphering the intracellular fate of *Propionibacterium acnes* in macrophages, Biomed. Res. Int. 2013 (2013) 603046, http://dx.doi.org/10.1155/2013/603046.

[28] A. Furukawa, K. Uchida, Y. Ishige, I. Ishige, I. Kobayashi, T. Takemura, T. Yokoyama, K. Iwai, K. Watanabe, S. Shimizu, N. Ishida, Y. Suzuki, T. Suzuki, T. Yamada, T. Ito, Y. Eishi, Characterization of *Propionibacterium acnes* isolates from sarcoid and non-sarcoid tissues with special reference to cell invasiveness, serotype, and trigger factor gene polymorphism, Microb. Pathog. 46 (2009) 80—87, http://dx.doi.org/10.1016/j.micpath.2008.10.013.

[29] Y. Yu, J. Champer, H. Garbán, J. Kim, Typing of *Propionibacterium acnes*: a review of methods and comparative analysis, Br. J. Dermatol (2015), http://dx.doi.org/10.1111/bjd.13667.

[30] F. Jasson, I. Nagy, A.C. Knol, T. Zuliani, A. Khammari, B. Dréno, Different strains of *Propionibacterium acnes* modulate differently the cutaneous innate immunity, Exp. Dermatol 22 (2013) 587—592, http://dx.doi.org/10.1111/exd.12206.

[31] F. Deknuydt, A. Roquilly, N. Cinotti, F. Altare, K. Asehnoune, An in vitro model of mycobacterial granuloma to investigate the immune response in brain-injured patients, Crit. Care Med. 41 (2013) 245—254, http://dx.doi.org/10.1097/CCM.0b013e3182676052.

[32] N. Alvarez-Rueda, M. Albassier, S. Allain, F. Deknuydt, F. Altare, P. Le Pape, First human model of in vitro *Candida albicans* persistence within granuloma for the reliable study of host-fungi interactions, PLoS One 7 (2012) e40185, http://dx.doi.org/10.1371/journal.pone.0040185.

[33] S. Landgraeber, M. von Knoch, F. Löer, J. Brankamp, M. Tsokos, F. Grabellus, K.W. Schmid, M. Totsch, Association between apoptotis and CD4(+)/CD8(+) T-lymphocyte ratio in aseptic loosening after total hip replacement, Int. J. Biol. Sci. 5 (2009) 182—191.

[34] M.E. Portillo, M. Salvadó, A. Alier, L. Sorli, S. Martínez, J.P. Horcajada, L. Puig, Prosthesis failure within 2 years of implantation is highly predictive of infection, Clin. Orthop. Relat. Res. 471 (2013) 3672—3678, http://dx.doi.org/10.1007/s11999-013-3200-7.

[35] W.S.J. Loke, C. Herbert, P.S. Thomas, Sarcoidosis: immunopathogenesis and immunological markers, Int. J. Chronic Dis. 2013 (2013) 928601, http://dx.doi.org/10.1155/2013/928601.

[36] M. Kistowska, B. Meier, T. Proust, L. Feldmeyer, A. Cozzio, T. Kuendig, E. Contassot, L.E. French, *Propionibacterium acnes* promotes Th17 and Th17/Th1 responses in acne patients, J. Invest. Dermatol 135 (2015) 110—118, http://dx.doi.org/10.1038/jid.2014.290.